0RIM Stock Overview
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
GenSight Biologics S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.41 |
52 Week High | €1.12 |
52 Week Low | €0.33 |
Beta | 2.14 |
1 Month Change | 3.24% |
3 Month Change | -0.48% |
1 Year Change | -34.61% |
3 Year Change | -95.45% |
5 Year Change | -78.23% |
Change since IPO | -91.77% |
Recent News & Updates
Recent updates
Shareholder Returns
0RIM | GB Biotechs | GB Market | |
---|---|---|---|
7D | 4.0% | 0.5% | 2.7% |
1Y | -34.6% | -29.8% | 0.3% |
Price Volatility
0RIM volatility | |
---|---|
0RIM Average Weekly Movement | 13.9% |
Biotechs Industry Average Movement | 7.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Volatility Over Time: 0RIM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 16 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
0RIM fundamental statistics | |
---|---|
Market cap | €31.76m |
Earnings (TTM) | -€26.22m |
Revenue (TTM) | €2.96m |
10.7x
P/S Ratio-1.2x
P/E RatioIs 0RIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0RIM income statement (TTM) | |
---|---|
Revenue | €2.96m |
Cost of Revenue | €0 |
Gross Profit | €2.96m |
Other Expenses | €29.18m |
Earnings | -€26.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 23, 2024
Earnings per share (EPS) | -0.34 |
Gross Margin | 100.00% |
Net Profit Margin | -884.62% |
Debt/Equity Ratio | -70.7% |
How did 0RIM perform over the long term?
See historical performance and comparison